
Govt Caps Ceiling Price Of 4 Emergency-Use Medicines, 37 Antibiotics, Painkillers
The prices were fixed by the National Pharmaceutical Pricing Authority (NPPA), and the medicines range from treating infections, heart ailments, and inflammation to diabetes and vitamin deficiencies.
"Manufacturers selling branded or generic or both versions of the medicines at a price higher than the ceiling price (plus GST) shall revise the prices downward not exceeding the ceiling price...," the NPPA said.
However, manufacturers having an MRP lower than the ceiling price shall continue to maintain the existing MRP, the NPPA added.
The emergency-use medicines include Ipratropium, used to prevent wheezing, shortness of breath, coughing, and chest tightness in people with chronic obstructive pulmonary disease. Its ceiling price was fixed at Rs 2.96 per ml.
For Sodium Nitroprusside, an injectable used to rapidly lower BP in hypertensive emergencies, during surgery to reduce bleeding, and in cases of acute heart failure, it was fixed at Rs 28.99 per ml; for Diltiazem, used to treat high BP and chest pain, it was fixed at Rs 26.72 per capsule; and for Povidone Iodine, used for skin disinfection before and after surgery and minor wound care, it was fixed at Rs 6.26 per gram.
Other medications with prices slashed include paracetamol, atorvastatin, amoxycillin, and metformin.
Among the drugs affected is a composition of Aceclofenac, Paracetamol, and Trypsin Chymotrypsin for use as an anti-inflammatory and cardiovascular drug, which comes as a combination of Atorvastatin 40 mg and Clopidogrel 75 mg.
According to the NPPA, the notified prices are GST-free, which may be charged additionally if needed.
It has also asked retailers and dealers to display new prices prominently and noted that non-compliance with the new rates would be punishable under the DPCO and the Essential Commodities Act, 1955. This would also involve the recovery of excess charged amounts with interest.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Bitmex Reports Over 185% Liquidity Growth Following AWS Tokyo Migration
- Tokenfi And New To The Street Announce National Media Partnership To Reach 219M+ Households
- Chartis Research And Metrika Release Comprehensive Framework For Managing Digital Asset Risk
- Xdata Group Named Among The Top 66 Saas Innovators In Techround's 2025 List
- Cregis At TOKEN2049 Singapore 2025: Unlocking The Next Frontier Of Adoption
- On-Chain Cultural Assets: Decoding City Protocol's IP Capital Market
Comments
No comment